News

The company reported net income for the second quarter of 2006 of $37.2 million compared with $26 million in the second quarter of last year. Diluted earnings per

Net sales for the second quarter increased to $228 million compared with $196.4 million in the second quarter of 2005. Diluted earnings per share for the three months

The three-month placebo-controlled clinical trial, which GTx initiated in May, is evaluating multiple doses of ostarine in 60 elderly men and 60 postmenopausal women. It is designed to

Results from the phase I/II study of betamethasone valerate 0.12% foam in plaque type psoriatic patients demonstrated that the Foamix’ product candidate was efficacious and safe. Patients also

Approximately 100 patients will be enrolled in the US and Canada and randomized into two treatment groups, with one treatment group receiving the combination of HGS-ETR1 and bortezomib,

The submission contains data from previously reported pivotal phase III studies that met their primary efficacy endpoints of reduction in incidence in menstrual migraine. If the supplemental new

Caraco’s Meloxicam Tablets is the generic equivalent of Boehringer Ingelheim’s Mobic, a nonsteroidal anti-inflammatory drug, (NSAID) indicated for the relief of the signs and symptoms of osteoarthritis. Caraco

The companies plan to combine operations in a stock transaction valued at approximately $8.8 million. As part of the merger, a portion of existing shares of Alteon preferred

An open-label phase II safety and efficacy trial enrolled 16 post-radical prostatectomy patients. Patients enrolled in the trial had undergone this surgery at least six months prior to